INVITES BIOCORE CO. LTD

As of December 31, 2025, INVITES BIOCORE CO. LTD carries a market capitalization of 34.88B, placing it among publicly traded companies globally. Its enterprise value stands at 64.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, INVITES BIOCORE CO. LTD has 7.66M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 2.10, and the price-to-book ratio stands at 13.14.

As of December 31, 2025, INVITES BIOCORE CO. LTD trades at an EV/EBITDA multiple of 20.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 294.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 64.30B versus a market cap of 34.88B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, INVITES BIOCORE CO. LTD maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,172.64, indicating moderate leverage, while an interest coverage ratio of 0.70 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, INVITES BIOCORE CO. LTD posted a negative return on equity (ROE) of -74.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.85, reflecting losses generated across the asset base. The company generates approximately 125.14M in revenue per employee across its workforce of 133.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.33 indicates how many times INVITES BIOCORE CO. LTD sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, INVITES BIOCORE CO. LTD recorded an income tax benefit of -88.63M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -7.86B and -6.19B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, INVITES BIOCORE CO. LTD's stock has declined approximately 62.80% over the past 52 weeks. The 50-day moving average sits at 1,210.96, while the 200-day moving average is 2,645.45.

Over the twelve months ended December 31, 2025, INVITES BIOCORE CO. LTD generated 16.64B in revenue and converted that into -6.19B in net income, yielding earnings per share of -1,014.74. EBITDA reached 3.09B, while operating income came in at 218.45M.

As of December 31, 2025, INVITES BIOCORE CO. LTD holds 1.71B in cash and equivalents against 31.13B in total debt, resulting in a net debt position of 27.62B. Total book value stands at 2.65B, with working capital of -63.65B providing operational flexibility.

INVITES BIOCORE CO. LTD produced 7.18B in operating cash flow over the twelve months ended December 31, 2025. After subtracting -3.55B in capital expenditures, free cash flow totaled 3.63B - equivalent to 473.98 per share.

Over the twelve months ended December 31, 2025, INVITES BIOCORE CO. LTD posted a gross margin of 27.67, reflecting its pricing power and cost economics. The operating margin of 1.31 and net profit margin of -37.20 provide insight into operational efficiency.

Over the twelve months ended December 31, 2025, INVITES BIOCORE CO. LTD paid dividends of 26.12 per share. The dividend payout ratio of -2.02 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 10.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 16.99, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to INVITES BIOCORE CO. LTD shareholders.

As of December 31, 2025, INVITES BIOCORE CO. LTD has an Altman Z-Score of -0.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.